Circle Internet Group Inc. Class A Common Stock vs Cytokinetics Inc — how do they compare? Circle Internet Group Inc. Class A Common Stock trades at $82.4 (market cap $20.52B), while Cytokinetics Inc trades at $62.02 (market cap $8.50B). The key difference: Circle Internet Group Inc. Class A Common Stock is far larger — about 2.4× Cytokinetics Inc's market cap, and Circle Internet Group Inc. Class A Common Stock is more actively traded (8,829,081 versus 2,395,556). Which is the better fit depends on your goals — on Pluang, investors hold Circle Internet Group Inc. Class A Common Stock for 0 Days and Cytokinetics Inc for 19 Days on average.
| CRCL | CYTK | |
|---|---|---|
Market Cap | $20.52B | $8.50B |
Volume | 8,829,081 | 2,395,556 |
Sector | Financials | Health |
52-Week High | $150.48 | $87.26 |
52-Week Low | $50.23 | $54.76 |
Typical Hold Time | 0 Days | 19 Days |
Enterprise Value | $19.03B | $8.60B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
CYTK trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages but bullish momentum from oscillators. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy, including Phase 3 results and real-world study launches.
Despite heavy losses, strong analyst consensus (97.14% buy ratings) and a $112.50 price target reflect optimism for its heart failure pipeline. Key risks include sustained cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization to justify its high P/S ratio of 112.42.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Circle Internet Group provides internet financial infrastructure centered on its stablecoin network. Its business includes stablecoins, blockchain infrastructure for developers, digital-asset services, and payment applications.
Read more on CRCL →Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →